EPH Receptor B4 抗体
(2 references)-
- 抗原 See all EPH Receptor B4 (EPHB4) 抗体
- EPH Receptor B4 (EPHB4)
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This EPH Receptor B4 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- 纯化方法
- purified
- 免疫原
- Purified recombinant fragment of EphB4 expressed in E. coli.
- 克隆位点
- 5B8F7
- 亚型
- IgG2a
- Top Product
- Discover our top product EPHB4 Primary Antibody
-
anti-EPH Receptor B4 (EPHB4) (AA 472-486), (Extracellular), (N-Term) antibody
EPHB4 适用: 人, 小鼠, 大鼠 WB, IHC, IF, FACS 宿主: 兔 Polyclonal unconjugated
anti-EPH Receptor B4 (EPHB4) (AA 300-540) antibodyEPHB4 适用: 人 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-EPH Receptor B4 (EPHB4) antibodyEPHB4 适用: 人 WB, ELISA, ICC 宿主: 小鼠 Monoclonal 5B5 unconjugated
anti-EPH Receptor B4 (EPHB4) (AA 198-323) antibodyEPHB4 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 4G11 unconjugated
anti-EPH Receptor B4 (EPHB4) (AA 562-612) antibodyEPHB4 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 7H4A6 unconjugated
anti-EPH Receptor B4 (EPHB4) antibodyEPHB4 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal RB14731 unconjugated
anti-EPH Receptor B4 (EPHB4) (Internal Region) antibodyEPHB4 适用: 人 WB, ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
anti-EPH Receptor B4 (EPHB4) (AA 889-923), (C-Term) antibodyEPHB4 适用: 人, 小鼠 WB 宿主: 兔 Polyclonal RB50408 unconjugated
anti-EPH Receptor B4 (EPHB4) (Internal Region) antibodyEPHB4 适用: 人, 小鼠 WB, ELISA, IHC, IF 宿主: 兔 Polyclonal unconjugated
anti-EPH Receptor B4 (EPHB4) (AA 198-323) antibodyEPHB4 适用: 人 ELISA 宿主: 小鼠 Monoclonal 1D1 unconjugated
-
- 应用备注
- ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- Ascitic fluid containing 0.03 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C/-20 °C
- 储存方法
- 4°C, -20°C for long term storage
-
-
: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." in: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).
: "Expression of Ephb2 and Ephb4 in breast carcinoma." in: Pathology oncology research : POR, Vol. 10, Issue 1, pp. 26-33, (2004) (PubMed).
-
: "Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity." in: Structure (London, England : 1993), Vol. 14, Issue 2, pp. 321-30, (2006) (PubMed).
-
- 抗原
- EPH Receptor B4 (EPHB4)
- 别名
- EphB4 (EPHB4 产品)
- 别名
- HTK antibody, MYK1 antibody, TYRO11 antibody, htk antibody, myk1 antibody, ephB4a antibody, tyro11 antibody, ephb4b antibody, MGC130997 antibody, AI042935 antibody, Htk antibody, MDK2 antibody, Myk1 antibody, Tyro11 antibody, cb646 antibody, ephB4 antibody, rtk5 antibody, EphB-rtk8 antibody, cb417 antibody, rtk8 antibody, EPH receptor B4 antibody, EPH receptor B4 L homeolog antibody, EPH receptor B4 S homeolog antibody, Eph receptor B4 antibody, eph receptor B4a antibody, eph receptor B4b antibody, EPHB4 antibody, ephb4.L antibody, ephb4.S antibody, ephb4 antibody, Ephb4 antibody, ephb4a antibody, ephb4b antibody
- 背景
-
Description: EPH receptor B4 (EphB4), with 987-amino acid protein (about 108 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. The Eph receptor tyrosine kinases and their ligands, the ephrins, regulate numerous biological processes in developing and adult tissues and have been implicated in cancer progression and in pathological forms of angiogenesis. EphB4 acts as a negative regulator of blood vessel branching and vascular network formation, switching the vascularization program from sprouting angiogenesis to circumferential vessel growth. EphB4 and its ligand ephrinB2 express in several kinds of tumor cells and correlate with tumorigenesis. EphB4 is thus a potential candidate as a predictor of disease outcome in several kinds of tumor and as target for novel therapy.
Aliases: HTK, MYK1, TYRO11
- 基因ID
- 2050
- HGNC
- 2050
- 途径
- RTK signaling
-
